查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1807979

神经调节设备市场按设备类型、控制机制、技术、年龄层、治疗领域、最终用户和分销管道划分 - 全球预测 2025-2030

Neuromodulation Devices Market by Device Type, Control Mechanism, Technology, Age Group, Therapeutic Area, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

神经调节设备市场预计在 2024 年价值 50.8 亿美元，在 2025 年成长至 54.5 亿美元，到 2030 年达到 78 亿美元，复合年增长率为 7.40%。

主要市场统计数据
基准年2024年 50.8亿美元
预计2025年 54.5亿美元
预测年份 2030 78亿美元
复合年增长率（%） 7.40%

展望神经调节设备的未来，重点在于新临床应用中的机会与挑战

神经调节装置透过向特定神经通路提供定向电刺激或磁刺激，彻底改变了复杂神经、精神和疼痛相关疾病的治疗。随着临床应用从帕金森氏症和慢性疼痛等既定适应症扩展到重度忧郁症和癫痫等新领域，相关人员必须适应快速的技术创新、不断变化的监管要求和日益激烈的竞争环境。本简介概述了当前产业格局的关键动态，并为深入分析提供了基础观点。

透过突破性创新和不断变化的患者需求，揭示神经调节设备产业的变革

在材料科学、数据分析和法规适应性突破的推动下，神经调节设备领域正在经历一场变革。生物相容性电极涂层和节能电池系统的最新进展，使得更小、更耐用、能够提供精确调节刺激的植入式设备得以开发。同时，由机器学习演算法驱动的软体创新正在简化个人化治疗通讯协定，提高回应率并减少不利事件。

分析2025年美国新关税对供应链动态和相关人员策略的累积影响

随着2025年美国新关税的实施，全球神经调节供应链将迎来重大曲折点。包括微电极和特种聚合物在内的精密零件的进口关税正在增加设备製造商的製造成本。为此，各公司正在调整筹资策略，并与国内供应商建立更紧密的伙伴关係关係，以减轻这些额外关税的影响。

关键细分洞察揭示了多样化的患者群体，技术和最终用户偏好推动着市场的发展

深层脑部刺激器和脊髓刺激设备等侵入式平台与经颅直流电刺激和经颅磁刺激等非侵入式治疗方式并存。在侵入式治疗领域，荐骨神经刺激器和迷走神经刺激设备为泌尿系统和消化系统疾病开闢了重要的治疗途径，而深部脑部刺激仍是运动障碍的黄金标准。另一方面，非侵入式技术正在透过提供风险更低、更便捷的门诊治疗程序，扩大其在精神疾病领域的应用。

了解美洲、欧洲、中东和非洲以及亚太地区的区域特征和战略成长机会

美洲生态系统以成熟的支付环境和先进的外科手术基础设施为特色。领先的学术医疗中心与设备製造商之间的前沿合作正在加速先进植入式系统的普及。同时，北美的报销政策非常严格，一旦获得可靠的临床证据，即可提供清晰的市场准入途径。因此，各公司正专注于纵向疗效研究，以满足不同相关人员的需求。

领先的神经调节设备製造商的策略和竞争定位将决定该行业的未来发展轨迹

领先的製造商正在采用独特的策略来巩固其在神经调节领域的地位。Medtronic正利用其在植入式技术领域的深厚专业知识和全球製造地，扩展其针对运动障碍的闭合迴路产品组合。与学术中心的合作提供了重要的长期安全性和有效性数据，增强了付款人的信心。波士顿科学以其在心臟和周边介入领域强大的产品组合而闻名，目前正在向脊髓刺激设备和荐骨神经刺激器领域拓展业务，并专注于支援远端监控的整合数位平台。

为行业领导者提供切实可行的建议，以应对监管复杂性和应用障碍，并加速神经调节领域的创新

产业领导者应优先开发封闭回路型神经调节系统，利用即时数据分析优化治疗效果。投资可互通的软体架构，可以无缝整合到现有的医院资讯系统和远端患者监护平台，从而提高临床医生的接受度，并增强支付方的证据产生能力。

严谨的调查方法细节，包括初步访谈、二次资料分析和三角测量，以获得可靠的市场洞察力

为确保研究结果的有效性和可靠性，本研究采用了全面的调查方法，包括一手资料研究和二手资料研究。二手资料研究包括深入检索公开的监管文件、同行评审期刊报导、临床试验註册中心和专利资料库。对这些资讯来源进行了系统分析，以确定关键地区的新兴技术趋势、资金筹措模式和不断变化的报销框架。

关于新兴神经调节设备技术利益相关相关人员的策略重要性和未来方向的考虑总结

摘要，神经调节设备产业正处于一个关键的十字路口，其特点是快速的技术创新、不断变化的监管模式以及相关人员不断变化的期望。闭合迴路和非侵入式治疗模式正在融合，以提高治疗精准度，而新的价格结构和供应链重组正在重塑商业策略。能够有效整合高阶分析技术、促进策略合作并维持供应链韧性的公司将成为产业领跑者。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 用于个人化神经治疗的封闭回路型深部脑部刺激系统的开发
  • 将非侵入性经颅磁刺激器与穿戴式健康监测器结合
  • 植入式迷走神经刺激设备在治疗难治性癫痫和忧郁症的进展
  • 一种用于精确无线神经迴路控制的新型光遗传神经调节方法
  • 监管核准流程简化了全球新型神经调节设备的临床试验
  • 采用人工智慧演算法即时优化刺激参数，以改善患者治疗效果
  • 增加对微型神经调节系统的投资，实现患者居家护理

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章神经调节设备市场（依设备类型）

  • 侵入性设备
    • 深层脑部刺激器
    • 荐骨神经刺激器
    • 脊髓刺激设备
    • 迷走神经刺激设备
  • 非侵入式设备
    • 经颅直流电刺激
    • 经颅磁刺激

9. 神经调节设备市场（依控制机制）

  • 闭合迴路
  • 开放回路

第 10 章 神经调节设备市场（依技术）

  • 电刺激
  • 磁刺激
  • 光遗传学刺激
  • 超音波刺激

第 11 章神经调节设备市场（依年龄层）

  • 成人
  • 老年人
  • 孩子们

第 12 章神经调节设备市场（按治疗领域）

  • 消化系统和泌尿系统疾病
  • 神经系统疾病
    • 肌张力不全症
    • 癫痫
    • 帕金森氏症
  • 疼痛管理
    • 慢性疼痛
    • 神经病变疼痛
  • 精神疾病
    • 忧郁症
    • 强迫症

第 13 章神经调节设备市场（依最终用户）

  • 门诊手术中心
  • 诊所
  • 医院
  • 研究所

第 14 章神经调节设备市场（依通路）

  • 离线
  • 在线的

第 15 章美洲神经调节设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 16 章欧洲、中东和非洲的神经调节设备市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第 17 章：亚太神经调节设备市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十八章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • Aleva Neurotherapeutics SA
    • Biotronik SE & Co. KG
    • Boston Scientific Corporation
    • BrainsWay Ltd.
    • ElectroCore, Inc.
    • Integer Holdings Corporation
    • Laborie
    • Life Science Outsourcing, Inc.
    • LivaNova PLC
    • Medtronic plc
    • Neuromod Devices Limited
    • Neuronetics, Inc.
    • Neuropace Inc.
    • NeuroSigma, Inc.
    • Nexstim Oyj
    • Saluda Medical Pty Ltd
    • Soterix Medical Inc.
    • Synapse Biomedical Inc.
    • Synergia Medical SA
    • tVNS Technologies GmbH

第十九章 研究人工智慧

第20章 研究统计

第21章 研究联络人

第22章 研究报导

第23章 附录

Product Code: MRR-205091A88963

The Neuromodulation Devices Market was valued at USD 5.08 billion in 2024 and is projected to grow to USD 5.45 billion in 2025, with a CAGR of 7.40%, reaching USD 7.80 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.08 billion
Estimated Year [2025] USD 5.45 billion
Forecast Year [2030] USD 7.80 billion
CAGR (%) 7.40%

Setting the Stage for the Future of Neuromodulation Devices by Highlighting Opportunities and Challenges in Emerging Clinical Applications

Neuromodulation devices are revolutionizing the treatment of complex neurological, psychiatric, and pain-related disorders by delivering targeted electrical or magnetic stimuli to specific neural pathways. As clinical applications expand from established indications such as Parkinson's disease and chronic pain into emerging areas like major depressive disorder and epilepsy, stakeholders must adapt to an environment defined by rapid innovation, evolving regulatory requirements, and escalating competition. This introduction outlines the crucial dynamics that underpin the current industry landscape, offering a foundational perspective for deeper analysis.

Firstly, the convergence of advanced hardware miniaturization and sophisticated algorithmic control mechanisms has driven the development of next-generation systems that prioritize safety, efficacy, and patient comfort. As closed loop feedback becomes more prevalent, the ability to monitor and adjust stimulation parameters in real time is setting new standards for therapeutic outcomes. Meanwhile, strategic investments in optogenetic and ultrasonic stimulation technologies are broadening the scope of neuromodulation, offering the potential to treat conditions previously deemed intractable.

Furthermore, the intersection of reimbursements, health economics, and stakeholder collaboration is redefining commercialization strategies. Payers and providers are increasingly demanding robust clinical evidence that demonstrates long-term cost-effectiveness. Consequently, successful market entrants will be those who not only innovate at the technical level but also build integrated value propositions aligned with evolving healthcare ecosystems.

Unraveling the Transformative Shifts Reshaping the Neuromodulation Device Industry through Breakthrough Innovations and Evolving Patient Needs

The neuromodulation device landscape is experiencing transformative shifts driven by breakthroughs in materials science, data analytics, and regulatory adaptation. Recent advances in biocompatible electrode coatings and energy-efficient battery systems have enabled the creation of implantable devices that are smaller, more durable, and capable of delivering precisely calibrated stimulation. At the same time, software innovations powered by machine learning algorithms are streamlining the personalization of therapy protocols, thereby improving response rates and reducing adverse events.

In parallel, the emergence of noninvasive technologies such as transcranial magnetic stimulation and transcranial direct current stimulation is redefining the treatment paradigm by offering outpatient solutions with minimal side effects. These modalities are gaining traction not only in major metropolitan healthcare centers but also in community clinics, where ease of use and patient comfort drive adoption. Regulatory bodies have responded by establishing more flexible frameworks that expedite clinical approvals while maintaining rigorous safety and performance standards.

Additionally, the growing trend toward decentralized clinical trials and real-world evidence collection is reshaping stakeholder expectations around data transparency and long-term outcome measurement. This shift underscores the need for robust post-market surveillance programs and interdisciplinary research collaborations. As a result, manufacturers and clinicians are coalescing around new models of evidence generation that leverage digital health platforms and patient-reported outcome measures to validate therapeutic value continuously.

Analyzing the Cumulative Impact of Newly Implemented United States Tariffs in 2025 on Supply Chain Dynamics and Stakeholder Strategies

The implementation of new United States tariffs in 2025 has introduced a significant inflection point in the global neuromodulation supply chain. Import duties on precision components, including microelectrodes and specialized polymers, have elevated production costs for device manufacturers. In response, companies are reevaluating their sourcing strategies and forging closer partnerships with domestic suppliers to mitigate the impact of these additional levies.

Moreover, the cumulative effect of tariff-related cost pressures is prompting organizations to revisit their pricing models and reimbursement negotiations. As device costs increase, healthcare providers and payers are demanding more comprehensive clinical data to justify higher reimbursement rates. Consequently, companies are accelerating investments in real-world evidence studies that demonstrate long-term cost savings and enhanced patient outcomes.

To address these challenges proactively, several leaders have reshaped their manufacturing footprints, relocating certain production lines to low-cost regions while retaining critical assembly and quality control processes domestically. This hybrid approach balances tariff avoidance with stringent compliance to U.S. regulatory standards. As a result, industry players are pioneering new operational frameworks that blend global efficiency with regional agility, thereby reinforcing supply chain resilience and sustaining market momentum.

Revealing Key Segmentation Insights to Illuminate Diverse Patient Populations Technologies and End User Preferences Driving Market Evolution

Diverse device typologies underpin the neuromodulation market's complexity, with invasive platforms such as deep brain stimulators and spinal cord stimulators coexisting alongside emerging noninvasive modalities including transcranial direct current stimulation and transcranial magnetic stimulation. Within the invasive category, sacral nerve stimulators and vagus nerve stimulators have unlocked critical treatment pathways for urinary and gastrointestinal disorders, whereas deep brain stimulation remains the gold standard for movement disorders. Conversely, noninvasive technologies are extending applications into psychiatric conditions, offering a lower-risk profile and simplified outpatient procedures.

Control mechanisms further differentiate competitive offerings, as closed loop systems integrate continuous neural feedback to adapt stimulation parameters dynamically, enhancing safety and efficacy. Open loop configurations, while established and cost-effective, are now complemented by these next-generation designs that promise higher therapeutic precision. As such, market participants are prioritizing investments in sensor integration and advanced analytics to support automated adjustments based on real-time patient data.

Underlying these mechanical distinctions, a spectrum of stimulation modalities-from electrical and magnetic to optogenetic and ultrasonic-provides a rich array of therapeutic options. Electrical stimulation remains the backbone of most implantable solutions, yet magnetic and ultrasonic techniques are gaining traction due to their noninvasive delivery and potential for finer spatial targeting. Concurrently, optogenetic approaches, still largely in experimental stages, herald a future where genetic modulation can be precisely controlled.

Age group considerations also play a vital role in technology adoption and clinical trial design. While adult and geriatric populations have historically been the primary focus, pediatric use cases are emerging in epilepsy management and certain movement disorders. These developments necessitate device miniaturization and tailored safety protocols to accommodate younger patients.

Disorders spanning neurological, psychiatric, pain management, and gastrointestinal or urological domains illustrate the breadth of therapeutic areas. Neurological conditions such as dystonia, epilepsy, and Parkinson's disease represent core applications, while chronic and neuropathic pain management regimes drive spinal cord stimulator utilization. Psychiatric indications including depression and obsessive-compulsive disorder are increasingly served by both invasive and noninvasive systems, reflecting interdisciplinary collaboration between neurology and psychiatry.

Lastly, end user channels vary from ambulatory surgical centers and high-acuity hospitals to specialized research institutes and outpatient clinics. Distribution pathways blend traditional offline channels with burgeoning online platforms that facilitate telehealth-enabled device monitoring and remote programming. This multi-faceted segmentation underscores the importance of customized strategies that align product features with clinical settings and patient preferences.

Deciphering Regional Nuances and Strategic Growth Opportunities across the Americas Europe Middle East Africa and Asia Pacific Territories

Within the Americas, the ecosystem is characterized by a mature payer environment and high levels of surgical infrastructure. Cutting-edge research collaborations between leading academic medical centers and device manufacturers have accelerated the adoption of advanced implantable systems. Meanwhile, reimbursement policies in North America, though stringent, provide a clear pathway for market entry once robust clinical evidence is secured. Consequently, companies are focusing on longitudinal outcome studies to satisfy diverse stakeholder requirements.

In Europe, the Middle East, and Africa region, heterogenous regulatory frameworks coexist alongside emerging initiatives to harmonize market access protocols. Western Europe continues to adopt noninvasive neuromodulation modalities at a favorable pace, driven by shared-value health economics models. At the same time, Gulf Cooperation Council countries demonstrate strong interest in advanced therapies, incentivizing pilot programs that showcase real-world benefits. Emerging markets in Africa remain nascent but present long-term growth potential as infrastructure investments and healthcare investments climb.

Asia-Pacific exhibits dynamic expansion fueled by government-led healthcare modernization and growing demand for minimally invasive treatments. Japan and Australia spearhead clinical acceptance of both invasive and noninvasive platforms, supported by local manufacturing incentives. In China and India, rapid urbanization and rising healthcare expenditure are catalyzing pilot reimbursement programs, challenging international companies to navigate country-specific regulations and distribution complexities effectively. As such, the region demands agile market entry strategies tailored to each jurisdiction's unique nuances.

Exploring Strategies and Competitive Positioning of Leading Neuromodulation Device Manufacturers Shaping the Industry's Future Trajectory

Leading manufacturers have adopted distinct strategies to fortify their positions within the neuromodulation domain. Medtronic has leveraged its deep expertise in implantable technologies and global manufacturing footprint to expand closed loop offerings for movement disorders. Its collaborations with academic centers have yielded critical long-term safety and efficacy data, enhancing payer confidence. Boston Scientific, known for its robust portfolio in cardiac and peripheral interventions, has diversified into spinal cord stimulators and sacral nerve stimulators, emphasizing integrated digital platforms that support remote monitoring.

Abbott has pursued a complementary approach, repurposing legacy hardware designs into modular systems that accommodate both electrical and ultrasonic stimulation. Its acquisition of smaller innovators has accelerated pipeline development in psychiatric indications, particularly depression. LivaNova, historically focused on epilepsy and vagus nerve stimulation, has deepened its research into optogenetics and next-generation electrode materials, positioning itself at the forefront of minimally invasive therapies. Meanwhile, emerging players such as NeuroPace and Cala Health are gaining traction with novel responsive neurostimulation systems that target refractory epilepsy and essential tremor through personalized algorithms.

Across the ecosystem, strategic partnerships are reshaping competitive dynamics. Collaboration agreements between medical device manufacturers and digital health specialists are enabling seamless integration of cloud-based analytics and patient engagement tools. Joint ventures with contract research organizations facilitate expedited clinical trial execution, while alliances with insurers ensure that real-world evidence is captured to support reimbursement dossiers. This multifaceted approach underscores the importance of adaptability and cross-sector collaboration in sustaining leadership and driving continued innovation.

Empowering Industry Leaders with Actionable Recommendations to Navigate Regulatory Complexities Adoption Barriers and Accelerate Innovation in Neuromodulation

Industry leaders should prioritize the development of closed loop neuromodulation systems that harness real-time data analytics to optimize therapeutic outcomes. By investing in interoperable software architectures, organizations can ensure seamless integration into existing hospital information systems and remote patient monitoring platforms. This will enhance clinician acceptance and strengthen evidence generation for payers.

Simultaneously, companies must forge strategic alliances with research institutes and key opinion leaders to co-design clinical trials that emphasize comparative effectiveness and health economic endpoints. This collaborative model not only accelerates enrollment but also enhances the robustness of data required for reimbursement submissions. Additionally, co-development agreements with digital health providers can facilitate hybrid care models that combine device therapy with telemedicine-enabled follow-up, thereby improving patient adherence and reducing overall care costs.

To mitigate supply chain volatility induced by geopolitical factors, it is advisable to adopt a dual-sourcing strategy for critical components, balancing domestic manufacturing capabilities with selective offshore partnerships. Leaders should also explore the repurposing of existing production lines to accommodate new device formats, thereby reducing capital expenditure. Finally, adopting an agile regulatory engagement framework-leveraging accelerated approval pathways and iterative feedback loops with health authorities-will shorten time to market and reinforce compliance.

By implementing these multifaceted recommendations, stakeholders can navigate complex regulatory and commercial landscapes while maintaining a competitive edge and delivering transformative therapies to patients in need.

Detailing a Rigorous Research Methodology Encompassing Primary Interviews Secondary Data Analysis and Triangulation for Robust Market Insights

This research adopted a comprehensive methodology featuring both primary and secondary research components to ensure the validity and reliability of insights. Initially, secondary research involved an extensive review of publicly available regulatory filings, peer-reviewed journal articles, clinical trial registries, and patent databases. These sources were systematically analyzed to identify emerging technological trends, funding patterns, and evolving reimbursement frameworks across key geographies.

Following this, primary research was conducted through in-depth interviews with over 30 stakeholders, including device manufacturers, leading neurologists, biomedical engineers, and health economic specialists. These interviews provided qualitative context around strategic priorities, operational challenges, and anticipated market developments. Interview findings were then cross-referenced with secondary data to validate conclusions and identify areas of consensus or divergence.

To triangulate data, we employed a multi-dimensional framework that integrated quantitative insights derived from regulatory approvals, clinical trial outcomes, and procurement tender analyses. This approach enabled the identification of consistent patterns and outliers. Rigorous quality checks were performed throughout the research process, including peer reviews and hypothesis validation sessions. By combining these robust methods, the study offers a holistic and actionable perspective on the neuromodulation landscape.

Concluding Reflections on the Strategic Imperatives and Future Directions for Stakeholders Engaging with Emerging Neuromodulation Device Technologies

In summary, the neuromodulation device industry is at a critical juncture defined by rapid technological innovation, shifting regulatory paradigms, and evolving stakeholder expectations. Closed loop and noninvasive modalities are converging to deliver enhanced therapeutic precision, while new tariff structures and supply chain realignments are reshaping operational strategies. Companies that effectively integrate advanced analytics, foster strategic collaborations, and maintain supply chain resilience will emerge as industry frontrunners.

Looking ahead, the pursuit of personalized medicine through optogenetic and ultrasonic stimulation holds the promise of unlocking new clinical applications. However, success will depend on the ability to generate compelling real-world evidence and navigate diverse regional reimbursement frameworks. By aligning technological development with patient-centric care models and interdisciplinary partnerships, stakeholders can capitalize on the transformative potential of neuromodulation to address unmet clinical needs and drive sustainable growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of closed-loop deep brain stimulation systems for personalized neurological therapies
  • 5.2. Integration of noninvasive transcranial magnetic stimulation devices with wearable health monitors
  • 5.3. Advancements in implantable vagus nerve stimulators for treatment-resistant epilepsy and depression
  • 5.4. Emerging optogenetic neuromodulation approaches for precise wireless neural circuit control
  • 5.5. Regulatory approval pathways streamlining novel neuromodulation device clinical trials globally
  • 5.6. Adoption of AI algorithms to optimize stimulation parameters in real time for patient outcomes
  • 5.7. Rising investment in miniaturized neuromodulation systems enabling at-home patient therapy

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Neuromodulation Devices Market, by Device Type

  • 8.1. Introduction
  • 8.2. Invasive Devices
    • 8.2.1. Deep Brain Stimulators
    • 8.2.2. Sacral Nerve Stimulators
    • 8.2.3. Spinal Cord Stimulators
    • 8.2.4. Vagus Nerve Stimulators
  • 8.3. Noninvasive Devices
    • 8.3.1. Transcranial Direct Current Stimulation
    • 8.3.2. Transcranial Magnetic Stimulation

9. Neuromodulation Devices Market, by Control Mechanism

  • 9.1. Introduction
  • 9.2. Closed Loop
  • 9.3. Open Loop

10. Neuromodulation Devices Market, by Technology

  • 10.1. Introduction
  • 10.2. Electrical Stimulation
  • 10.3. Magnetic Stimulation
  • 10.4. Optogenetic Stimulation
  • 10.5. Ultrasonic Stimulation

11. Neuromodulation Devices Market, by Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Neuromodulation Devices Market, by Therapeutic Area

  • 12.1. Introduction
  • 12.2. Gastrointestinal & Urological Disorders
  • 12.3. Neurological Disorders
    • 12.3.1. Dystonia
    • 12.3.2. Epilepsy
    • 12.3.3. Parkinson's Disease
  • 12.4. Pain Management
    • 12.4.1. Chronic Pain
    • 12.4.2. Neuropathic Pain
  • 12.5. Psychiatric Disorders
    • 12.5.1. Depression
    • 12.5.2. Obsessive-Compulsive Disorder

13. Neuromodulation Devices Market, by End User

  • 13.1. Introduction
  • 13.2. Ambulatory Surgical Centers
  • 13.3. Clinics
  • 13.4. Hospitals
  • 13.5. Research Institutes

14. Neuromodulation Devices Market, by Distribution Channel

  • 14.1. Introduction
  • 14.2. Offline
  • 14.3. Online

15. Americas Neuromodulation Devices Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Neuromodulation Devices Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Neuromodulation Devices Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. Aleva Neurotherapeutics SA
    • 18.3.3. Biotronik SE & Co. KG
    • 18.3.4. Boston Scientific Corporation
    • 18.3.5. BrainsWay Ltd.
    • 18.3.6. ElectroCore, Inc.
    • 18.3.7. Integer Holdings Corporation
    • 18.3.8. Laborie
    • 18.3.9. Life Science Outsourcing, Inc.
    • 18.3.10. LivaNova PLC
    • 18.3.11. Medtronic plc
    • 18.3.12. Neuromod Devices Limited
    • 18.3.13. Neuronetics, Inc.
    • 18.3.14. Neuropace Inc.
    • 18.3.15. NeuroSigma, Inc.
    • 18.3.16. Nexstim Oyj
    • 18.3.17. Saluda Medical Pty Ltd
    • 18.3.18. Soterix Medical Inc.
    • 18.3.19. Synapse Biomedical Inc.
    • 18.3.20. Synergia Medical SA
    • 18.3.21. tVNS Technologies GmbH

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. NEUROMODULATION DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. NEUROMODULATION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROMODULATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. NEUROMODULATION DEVICES MARKET: RESEARCHAI
  • FIGURE 30. NEUROMODULATION DEVICES MARKET: RESEARCHSTATISTICS
  • FIGURE 31. NEUROMODULATION DEVICES MARKET: RESEARCHCONTACTS
  • FIGURE 32. NEUROMODULATION DEVICES MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NEUROMODULATION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SACRAL NERVE STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SACRAL NERVE STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SPINAL CORD STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SPINAL CORD STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLOSED LOOP, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPEN LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPEN LOOP, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY MAGNETIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY MAGNETIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPTOGENETIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPTOGENETIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ULTRASONIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ULTRASONIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GASTROINTESTINAL & UROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GASTROINTESTINAL & UROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DYSTONIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 209. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 231. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 232. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 299. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 303. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 305. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 306. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 307. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 309. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)

TAB